277 related articles for article (PubMed ID: 38339374)
1. Chimeric Antigen Receptor T Cell and Chimeric Antigen Receptor NK Cell Therapy in Pediatric and Adult High-Grade Glioma-Recent Advances.
Kowalczyk A; Zarychta J; Marszołek A; Zawitkowska J; Lejman M
Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339374
[TBL] [Abstract][Full Text] [Related]
2. CAR-T Therapy for Pediatric High-Grade Gliomas: Peculiarities, Current Investigations and Future Strategies.
Antonucci L; Canciani G; Mastronuzzi A; Carai A; Del Baldo G; Del Bufalo F
Front Immunol; 2022; 13():867154. PubMed ID: 35603195
[TBL] [Abstract][Full Text] [Related]
3. Applications and current challenges of chimeric antigen receptor T cells in treating high-grade gliomas in adult and pediatric populations.
Jovanovich N; Habib A; Hameed NF; Edwards L; Zinn PO
Immunotherapy; 2023 Apr; 15(5):383-396. PubMed ID: 36876438
[TBL] [Abstract][Full Text] [Related]
4. Next Generation CAR T Cells for the Immunotherapy of High-Grade Glioma.
Petersen CT; Krenciute G
Front Oncol; 2019; 9():69. PubMed ID: 30863720
[TBL] [Abstract][Full Text] [Related]
5. CAR-NK cell therapy for glioblastoma: what to do next?
Xiong Q; Zhu J; Zhang Y; Deng H
Front Oncol; 2023; 13():1192128. PubMed ID: 37404752
[TBL] [Abstract][Full Text] [Related]
6. Potential of chimeric antigen receptor (CAR)-redirected immune cells in breast cancer therapies: Recent advances.
Nikoo M; Rudiansyah M; Bokov DO; Jainakbaev NT; Suksatan W; Ansari MJ; Thangavelu L; Chupradit S; Zamani A; Adili A; Shomali N; Akbari M
J Cell Mol Med; 2022 Aug; 26(15):4137-4156. PubMed ID: 35762299
[TBL] [Abstract][Full Text] [Related]
7. CAR T-cell therapy: a potential treatment strategy for pediatric midline gliomas.
Das AK; Sinha M; Singh SK; Chaudhary A; Boro AK; Agrawal M; Bhardwaj S; Kishore S; Kumari K
Acta Neurol Belg; 2024 Apr; ():. PubMed ID: 38669002
[TBL] [Abstract][Full Text] [Related]
8. T-Cell Immunotherapy for Pediatric High-Grade Gliomas: New Insights to Overcoming Therapeutic Challenges.
Haydar D; Ibañez-Vega J; Krenciute G
Front Oncol; 2021; 11():718030. PubMed ID: 34760690
[TBL] [Abstract][Full Text] [Related]
9. Development of immunotherapy for high-grade gliomas: Overcoming the immunosuppressive tumor microenvironment.
Franson A; McClellan BL; Varela ML; Comba A; Syed MF; Banerjee K; Zhu Z; Gonzalez N; Candolfi M; Lowenstein P; Castro MG
Front Med (Lausanne); 2022; 9():966458. PubMed ID: 36186781
[TBL] [Abstract][Full Text] [Related]
10. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
[TBL] [Abstract][Full Text] [Related]
11. Future development of chimeric antigen receptor T cell therapies for patients suffering from malignant glioma.
Watchmaker PB; Colton M; Pineo-Cavanaugh PL; Okada H
Curr Opin Oncol; 2022 Nov; 34(6):661-669. PubMed ID: 35855503
[TBL] [Abstract][Full Text] [Related]
12. Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects.
Elahi R; Heidary AH; Hadiloo K; Esmaeilzadeh A
Stem Cell Rev Rep; 2021 Dec; 17(6):2081-2106. PubMed ID: 34472037
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor efficacy of anti-GD2 CAR NK-92 cells in diffuse intrinsic pontine gliomas.
Zuo P; Li Y; He C; Wang T; Zheng X; Liu H; Wu Z; Zhang J; Liao X; Zhang L
Front Immunol; 2023; 14():1145706. PubMed ID: 37251413
[TBL] [Abstract][Full Text] [Related]
14. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions.
Zhang P; Zhang Y; Ji N
Front Immunol; 2022; 13():927132. PubMed ID: 35874698
[TBL] [Abstract][Full Text] [Related]
15. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances.
Maalej KM; Merhi M; Inchakalody VP; Mestiri S; Alam M; Maccalli C; Cherif H; Uddin S; Steinhoff M; Marincola FM; Dermime S
Mol Cancer; 2023 Jan; 22(1):20. PubMed ID: 36717905
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor-natural killer cells: Novel insight into immunotherapy for solid tumors (Review).
Peng X; Chen L; Chen L; Wang B; Wang Y; Zhan X
Exp Ther Med; 2021 Apr; 21(4):340. PubMed ID: 33732313
[TBL] [Abstract][Full Text] [Related]
17. Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors.
Jan CI; Huang SW; Canoll P; Bruce JN; Lin YC; Pan CM; Lu HM; Chiu SC; Cho DY
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663641
[TBL] [Abstract][Full Text] [Related]
18. NK Cell-Based Immunotherapy and Therapeutic Perspective in Gliomas.
Pan C; Zhai Y; Li G; Jiang T; Zhang W
Front Oncol; 2021; 11():751183. PubMed ID: 34765554
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV.
Liu D; Tian S; Zhang K; Xiong W; Lubaki NM; Chen Z; Han W
Protein Cell; 2017 Dec; 8(12):861-877. PubMed ID: 28488245
[TBL] [Abstract][Full Text] [Related]
20. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.
Pan K; Farrukh H; Chittepu VCSR; Xu H; Pan CX; Zhu Z
J Exp Clin Cancer Res; 2022 Mar; 41(1):119. PubMed ID: 35361234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
